<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<title>Roche Diagnostics â€” Theta Framework Case Study</title>
<link rel="preconnect" href="https://fonts.googleapis.com">
<link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
<link href="https://fonts.googleapis.com/css2?family=Playfair+Display:ital,wght@0,400;0,500;0,600;1,400;1,500&family=Outfit:wght@300;400;500;600&display=swap" rel="stylesheet">
<script src="https://cdnjs.cloudflare.com/ajax/libs/Chart.js/4.4.1/chart.umd.min.js"></script>
<style>
:root {
  --roche-blue: #0066CC;
  --roche-blue-deep: #004A99;
  --roche-blue-light: #3388DD;
  --roche-accent: #00AAFF;
  --roche-gold: #C8963C;
  --ink: #080F1C;
  --ink-soft: #121D2E;
  --paper: #F5F4F1;
  --paper-warm: #ECEAE3;
  --muted: #7A8599;
  --core-green: #1A6B4A;
  --edge-amber: #B07B1A;
  --beyond-crimson: #7A1A2E;
  --border: rgba(0,102,204,0.12);
}
*,*::before,*::after{box-sizing:border-box;margin:0;padding:0;}
html{scroll-behavior:smooth;}
body{font-family:'Outfit',sans-serif;background:var(--paper);color:var(--ink);overflow-x:hidden;}

/* NAV */
nav{
  position:fixed;top:0;left:0;right:0;z-index:100;
  display:flex;align-items:center;justify-content:space-between;
  padding:0 52px;height:62px;
  background:rgba(8,15,28,0.88);
  backdrop-filter:blur(20px);
  border-bottom:1px solid rgba(0,102,204,0.15);
}
.nav-logo{
  font-family:'Playfair Display',serif;
  font-size:16px;font-weight:500;letter-spacing:0.12em;
  color:var(--roche-accent);text-transform:uppercase;
}
.nav-links{display:flex;gap:28px;}
.nav-links a{
  font-size:10px;font-weight:500;letter-spacing:0.16em;
  text-transform:uppercase;color:rgba(255,255,255,0.3);
  text-decoration:none;transition:color 0.2s;
}
.nav-links a:hover{color:var(--roche-accent);}

/* HERO */
.hero{
  height:100vh;min-height:760px;
  background:var(--ink);
  position:relative;overflow:hidden;
  display:flex;flex-direction:column;justify-content:flex-end;
  padding:0 10vw 80px;
}
.hero-grid{
  position:absolute;inset:0;
  background-image:
    linear-gradient(rgba(0,102,204,0.04) 1px,transparent 1px),
    linear-gradient(90deg,rgba(0,102,204,0.04) 1px,transparent 1px);
  background-size:72px 72px;
}
.hero-orb1{
  position:absolute;right:-120px;top:-100px;
  width:760px;height:760px;border-radius:50%;
  background:radial-gradient(ellipse,rgba(0,102,204,0.16) 0%,transparent 60%);
  pointer-events:none;
}
.hero-orb2{
  position:absolute;left:-80px;bottom:-60px;
  width:500px;height:500px;border-radius:50%;
  background:radial-gradient(ellipse,rgba(0,170,255,0.06) 0%,transparent 65%);
  pointer-events:none;
}
.hero-dna{
  position:absolute;right:8vw;top:50%;transform:translateY(-50%);
  opacity:0.03;pointer-events:none;
  font-family:'Playfair Display',serif;
  font-size:40vw;font-weight:400;line-height:1;
  color:#fff;user-select:none;letter-spacing:-0.06em;
}
.hero-label{
  font-size:9px;font-weight:500;letter-spacing:0.28em;
  text-transform:uppercase;color:var(--roche-accent);
  margin-bottom:28px;display:block;
  opacity:0;animation:fadeUp 0.8s 0.2s forwards;
}
.hero-content{position:relative;z-index:2;}
.hero-headline{
  font-family:'Playfair Display',serif;
  font-size:clamp(36px,5.2vw,80px);
  font-weight:400;line-height:1.08;
  color:#fff;margin-bottom:26px;
  opacity:0;animation:fadeUp 0.9s 0.4s forwards;
}
.hero-headline em{font-style:italic;color:var(--roche-accent);}
.hero-sub{
  font-size:15px;font-weight:300;line-height:1.84;
  color:rgba(255,255,255,0.38);max-width:560px;
  margin-bottom:60px;
  opacity:0;animation:fadeUp 0.9s 0.6s forwards;
}
.hero-meta{
  display:flex;gap:52px;
  border-top:1px solid rgba(255,255,255,0.07);
  padding-top:28px;
  opacity:0;animation:fadeUp 0.9s 0.8s forwards;
}
.meta-item{display:flex;flex-direction:column;gap:5px;}
.meta-label{font-size:9px;font-weight:500;letter-spacing:0.2em;text-transform:uppercase;color:rgba(255,255,255,0.22);}
.meta-value{font-family:'Playfair Display',serif;font-size:21px;font-weight:400;color:#fff;}
.scroll-cue{
  position:absolute;right:48px;bottom:52px;
  display:flex;flex-direction:column;align-items:center;gap:9px;
  opacity:0;animation:fadeIn 1s 1.4s forwards;
}
.scroll-line{width:1px;height:56px;background:linear-gradient(to bottom,transparent,var(--roche-blue-light));animation:pulse 2.8s ease-in-out infinite;}
.scroll-text{font-size:8px;letter-spacing:0.22em;text-transform:uppercase;color:rgba(255,255,255,0.18);writing-mode:vertical-rl;}
@keyframes pulse{0%,100%{opacity:0.2;transform:scaleY(0.5)}50%{opacity:1;transform:scaleY(1)}}
@keyframes fadeUp{from{opacity:0;transform:translateY(22px)}to{opacity:1;transform:translateY(0)}}
@keyframes fadeIn{from{opacity:0}to{opacity:1}}

/* SECTIONS */
section{padding:100px 10vw;}
section.white{background:#fff;}
section.warm{background:var(--paper-warm);}
section.ink{background:var(--ink);color:#fff;}
.section-label{font-size:9px;font-weight:500;letter-spacing:0.26em;text-transform:uppercase;color:var(--roche-blue);margin-bottom:14px;}
.section-title{font-family:'Playfair Display',serif;font-size:clamp(28px,3.4vw,50px);font-weight:400;line-height:1.12;margin-bottom:56px;}
.section-title em{font-style:italic;color:var(--roche-blue);}
.ink .section-title{color:#fff;}
.ink .section-title em{color:var(--roche-accent);}
.ink .section-label{color:rgba(0,170,255,0.5);}

/* ABOUT */
.about-grid{display:grid;grid-template-columns:1.1fr 0.9fr;gap:80px;align-items:start;}
.about-prose p{font-size:15px;line-height:1.9;color:#2A3442;margin-bottom:20px;font-weight:300;}
.dark-card{
  margin-top:38px;padding:30px 32px;
  background:var(--ink);border-radius:2px;
  border-left:2px solid var(--roche-gold);
}
.dark-card-label{font-size:8px;letter-spacing:0.22em;text-transform:uppercase;color:var(--roche-gold);margin-bottom:11px;}
.dark-card p{font-size:13px;line-height:1.82;color:rgba(255,255,255,0.52);}
.stat-grid{display:grid;grid-template-columns:1fr 1fr;gap:2px;}
.stat-box{padding:32px 26px;background:var(--paper-warm);border:1px solid var(--border);transition:background 0.22s;}
.stat-box:hover{background:#fff;}
.stat-num{font-family:'Playfair Display',serif;font-size:44px;font-weight:400;color:var(--roche-blue);line-height:1;margin-bottom:8px;}
.stat-desc{font-size:11.5px;color:var(--muted);line-height:1.58;}

.belief-strip{
  margin-top:72px;padding:60px 10vw;
  background:linear-gradient(135deg,#00214A 0%,#003D80 50%,#00214A 100%);
  text-align:center;position:relative;overflow:hidden;
}
.belief-strip::before{content:'';position:absolute;inset:0;background:radial-gradient(ellipse at 50% 50%,rgba(0,170,255,0.08) 0%,transparent 65%);}
.belief-strip::after{content:'"';position:absolute;left:7vw;top:-30px;font-family:'Playfair Display',serif;font-size:300px;font-weight:400;line-height:1;color:rgba(0,102,204,0.1);pointer-events:none;}
.belief-quote{font-family:'Playfair Display',serif;font-size:clamp(18px,2.2vw,30px);font-weight:400;font-style:italic;color:rgba(255,255,255,0.92);line-height:1.58;max-width:820px;margin:0 auto 20px;position:relative;z-index:1;}
.belief-attr{font-size:11px;letter-spacing:0.16em;text-transform:uppercase;color:var(--roche-accent);position:relative;z-index:1;}

/* BELIEFS GRID */
.beliefs-grid{display:grid;grid-template-columns:repeat(3,1fr);gap:2px;background:var(--border);border:1px solid var(--border);}
.belief-card{padding:34px 28px;background:#fff;transition:background 0.22s;}
.belief-card:hover{background:var(--paper-warm);}
.belief-num{font-family:'Playfair Display',serif;font-size:48px;font-weight:400;color:rgba(0,102,204,0.1);line-height:1;margin-bottom:14px;}
.belief-title{font-size:13px;font-weight:600;letter-spacing:0.02em;margin-bottom:10px;color:var(--ink);}
.belief-body{font-size:13px;line-height:1.76;color:#46555A;font-weight:300;}

/* TIMELINE */
.timeline{position:relative;padding-left:160px;}
.tl-spine{position:absolute;left:128px;top:0;bottom:0;width:1px;background:linear-gradient(to bottom,transparent,var(--roche-blue) 7%,var(--roche-blue) 93%,transparent);}
.tl-item{position:relative;margin-bottom:58px;}
.tl-year{position:absolute;left:-160px;width:120px;font-family:'Playfair Display',serif;font-size:23px;font-weight:400;color:var(--roche-blue);text-align:right;padding-top:2px;}
.tl-dot{position:absolute;left:-37px;top:9px;width:14px;height:14px;border-radius:50%;border:2px solid var(--roche-blue);background:var(--paper-warm);z-index:2;}
.tl-dot.filled{background:var(--roche-blue);}
.tl-dot.accent{background:var(--roche-gold);border-color:var(--roche-gold);box-shadow:0 0 0 4px rgba(200,150,60,0.15);}
.tl-phase{font-size:8px;letter-spacing:0.2em;text-transform:uppercase;color:var(--roche-gold);margin-bottom:7px;}
.tl-event{font-family:'Playfair Display',serif;font-size:22px;font-weight:500;margin-bottom:8px;color:var(--ink);}
.tl-desc{font-size:13.5px;line-height:1.8;color:#46555A;max-width:620px;font-weight:300;}

/* THETA MAP */
.theta-wrap{display:grid;grid-template-columns:1fr 1.7fr;gap:64px;align-items:start;}
.zone-pill{padding:16px 20px;border-radius:2px;border-left:3px solid;margin-bottom:12px;}
.zone-pill.core{border-color:var(--core-green);background:rgba(26,107,74,0.05);}
.zone-pill.edge{border-color:var(--edge-amber);background:rgba(176,123,26,0.05);}
.zone-pill.beyond{border-color:var(--beyond-crimson);background:rgba(122,26,46,0.05);}
.zone-pill-name{font-size:10px;font-weight:600;letter-spacing:0.1em;text-transform:uppercase;margin-bottom:5px;}
.zone-pill.core .zone-pill-name{color:var(--core-green);}
.zone-pill.edge .zone-pill-name{color:var(--edge-amber);}
.zone-pill.beyond .zone-pill-name{color:var(--beyond-crimson);}
.zone-pill-desc{font-size:12px;color:var(--muted);line-height:1.54;font-weight:300;}
.reading-box{margin-top:24px;padding:20px 22px;background:var(--ink);border-radius:2px;}
.reading-box-label{font-size:8px;letter-spacing:0.18em;text-transform:uppercase;color:var(--roche-accent);margin-bottom:10px;}
.reading-box p{font-size:12.5px;line-height:1.72;color:rgba(255,255,255,0.48);font-weight:300;}
.chart-h{height:480px;position:relative;}

/* ALLOCATION */
.alloc-grid{display:grid;grid-template-columns:1fr 1fr;gap:64px;align-items:center;}
.donut-wrap{position:relative;height:290px;display:flex;align-items:center;justify-content:center;}
.donut-center{position:absolute;text-align:center;pointer-events:none;}
.donut-center-lbl{font-size:9px;letter-spacing:0.14em;text-transform:uppercase;color:var(--muted);display:block;margin-bottom:4px;}
.donut-center-val{font-family:'Playfair Display',serif;font-size:38px;font-weight:400;color:var(--ink);display:block;line-height:1;}
.alloc-bars{display:flex;flex-direction:column;gap:28px;}
.bar-header{display:flex;justify-content:space-between;align-items:baseline;margin-bottom:9px;}
.bar-name{font-size:11px;font-weight:600;letter-spacing:0.08em;text-transform:uppercase;}
.bar-pcts{font-size:11.5px;color:var(--muted);}
.bar-track{height:5px;background:rgba(0,0,0,0.07);border-radius:99px;position:relative;overflow:visible;}
.bar-fill{height:100%;border-radius:99px;}
.bar-bm{position:absolute;top:-5px;width:2px;height:15px;background:var(--ink);opacity:0.18;}
.bar-comment{font-size:12px;color:var(--muted);margin-top:8px;line-height:1.6;font-weight:300;}

/* COMPETITORS */
.comp-grid{display:grid;grid-template-columns:repeat(5,1fr);gap:12px;margin-bottom:60px;}
.comp-card{padding:24px 18px;background:var(--paper-warm);border:1px solid var(--border);border-radius:2px;transition:transform 0.2s,box-shadow 0.2s;}
.comp-card:hover{transform:translateY(-3px);box-shadow:0 8px 24px rgba(0,0,0,0.07);}
.comp-card.featured{border-color:rgba(0,102,204,0.35);background:rgba(0,102,204,0.04);}
.comp-name{font-family:'Playfair Display',serif;font-size:19px;font-weight:500;margin-bottom:4px;}
.comp-tag{font-size:10.5px;color:var(--muted);margin-bottom:16px;line-height:1.42;font-weight:300;}
.comp-zones{display:flex;flex-direction:column;gap:7px;margin-bottom:16px;}
.comp-zone-row{display:flex;align-items:flex-start;gap:8px;font-size:11.5px;line-height:1.42;color:#46555A;font-weight:300;}
.zdot{width:7px;height:7px;border-radius:50%;flex-shrink:0;margin-top:3px;}
.zdot.core{background:var(--core-green);}
.zdot.edge{background:var(--edge-amber);}
.zdot.beyond{background:var(--beyond-crimson);}
.verdict-chip{font-size:9px;font-weight:600;letter-spacing:0.07em;text-transform:uppercase;padding:4px 10px;border-radius:99px;display:inline-block;}
.verdict-chip.leader{background:rgba(26,107,74,0.12);color:var(--core-green);}
.verdict-chip.challenger{background:rgba(176,123,26,0.12);color:var(--edge-amber);}
.verdict-chip.laggard{background:rgba(122,26,46,0.12);color:var(--beyond-crimson);}
.radar-wrap{height:360px;max-width:640px;margin:0 auto;}

/* S&W */
.sw-grid{display:grid;grid-template-columns:1fr 1fr;gap:40px;}
.sw-panel{padding:36px;border-radius:2px;}
.sw-panel.str{background:rgba(26,107,74,0.04);border:1px solid rgba(26,107,74,0.18);}
.sw-panel.wk{background:rgba(122,26,46,0.04);border:1px solid rgba(122,26,46,0.14);}
.sw-title{font-family:'Playfair Display',serif;font-size:26px;font-weight:500;margin-bottom:28px;}
.sw-panel.str .sw-title{color:var(--core-green);}
.sw-panel.wk .sw-title{color:var(--beyond-crimson);}
.sw-item{display:flex;gap:14px;margin-bottom:22px;}
.sw-marker{width:26px;height:26px;border-radius:50%;flex-shrink:0;display:flex;align-items:center;justify-content:center;font-size:10px;font-weight:600;margin-top:2px;}
.str .sw-marker{background:rgba(26,107,74,0.1);color:var(--core-green);}
.wk .sw-marker{background:rgba(122,26,46,0.09);color:var(--beyond-crimson);}
.sw-lead{font-size:13.5px;font-weight:600;margin-bottom:5px;}
.sw-body{font-size:12.5px;line-height:1.72;color:#46555A;font-weight:300;}

/* DIAGNOSTIC */
.diag-grid{display:grid;grid-template-columns:1fr 1fr;gap:64px;}
.diag-block{margin-bottom:36px;}
.diag-block-title{font-size:9px;letter-spacing:0.2em;text-transform:uppercase;color:rgba(0,170,255,0.5);margin-bottom:14px;padding-bottom:10px;border-bottom:1px solid rgba(0,102,204,0.16);}
.arch-row{display:flex;gap:8px;margin-bottom:12px;flex-wrap:wrap;}
.arch-box{padding:7px 13px;border-radius:2px;font-size:10.5px;font-weight:600;letter-spacing:0.06em;}
.arch-box.ok{background:rgba(26,107,74,0.18);color:#6fcf97;}
.arch-box.mid{background:rgba(176,123,26,0.18);color:#E0A040;}
.arch-box.low{background:rgba(122,26,46,0.18);color:#f08080;}
.diag-prose{font-size:13.5px;line-height:1.82;color:rgba(255,255,255,0.52);font-weight:300;}
.tension-box{padding:24px 22px;background:rgba(0,102,204,0.07);border:1px solid rgba(0,102,204,0.2);border-radius:2px;margin-top:16px;}
.tension-label{font-size:9px;letter-spacing:0.18em;text-transform:uppercase;color:var(--roche-accent);margin-bottom:10px;}
.tension-text{font-size:13.5px;line-height:1.82;color:rgba(255,255,255,0.58);font-style:italic;font-weight:300;}
.ibr{display:flex;align-items:center;gap:12px;margin-bottom:14px;}
.ibr-label{font-size:11px;color:rgba(255,255,255,0.44);width:56px;flex-shrink:0;font-weight:300;}
.ibr-track{flex:1;height:4px;background:rgba(255,255,255,0.07);border-radius:99px;position:relative;overflow:visible;}
.ibr-fill{height:100%;border-radius:99px;}
.ibr-bm{position:absolute;top:-5px;width:1px;height:14px;background:rgba(255,255,255,0.2);}
.ibr-pct{font-size:10.5px;color:rgba(255,255,255,0.28);width:34px;text-align:right;flex-shrink:0;}
.verdict-final{margin-top:36px;padding:28px 32px;background:rgba(0,102,204,0.09);border:1px solid rgba(0,102,204,0.22);border-radius:2px;}
.verdict-type{font-family:'Playfair Display',serif;font-size:30px;font-weight:400;color:#fff;margin-bottom:10px;}
.verdict-symbols{font-size:18px;margin-bottom:12px;letter-spacing:0.09em;}
.verdict-explain{font-size:13.5px;line-height:1.82;color:rgba(255,255,255,0.52);font-weight:300;}

/* REVEAL */
.reveal{opacity:0;transform:translateY(24px);transition:opacity 0.72s ease,transform 0.72s ease;}
.reveal.visible{opacity:1;transform:translateY(0);}

/* FOOTER */
footer{background:var(--ink);padding:32px 10vw;display:flex;justify-content:space-between;align-items:center;border-top:1px solid rgba(0,102,204,0.1);}
.footer-l{font-size:11.5px;color:rgba(255,255,255,0.22);letter-spacing:0.05em;}
.footer-l strong{color:rgba(255,255,255,0.38);}
.footer-r{font-size:10px;letter-spacing:0.18em;text-transform:uppercase;color:rgba(255,255,255,0.15);}

/* REVENUE CHART */
.rev-wrap{height:240px;margin-top:52px;}
.chart-label{font-size:9px;letter-spacing:0.18em;text-transform:uppercase;color:var(--roche-blue);margin-bottom:10px;}

/* SPINOFFS / THE ARCHITECTURE  */
.arch-card-grid{display:grid;grid-template-columns:repeat(3,1fr);gap:2px;background:var(--border);border:1px solid var(--border);margin-bottom:52px;}
.arch-card{padding:30px 24px;background:#fff;transition:background 0.22s;}
.arch-card:hover{background:var(--paper-warm);}
.arch-card-yr{font-family:'Playfair Display',serif;font-size:36px;font-weight:400;color:rgba(0,102,204,0.22);line-height:1;margin-bottom:10px;}
.arch-card-name{font-size:14px;font-weight:600;margin-bottom:6px;color:var(--ink);}
.arch-card-desc{font-size:12px;line-height:1.64;color:var(--muted);margin-bottom:12px;font-weight:300;}
.arch-card-status{font-size:10px;font-weight:600;letter-spacing:0.07em;text-transform:uppercase;padding:3px 9px;border-radius:99px;display:inline-block;}
.arch-card-status.live{background:rgba(26,107,74,0.1);color:var(--core-green);}
.arch-card-status.growing{background:rgba(0,102,204,0.1);color:var(--roche-blue);}
.arch-card-status.challenge{background:rgba(176,123,26,0.1);color:var(--edge-amber);}

@media(max-width:900px){
  nav{padding:0 24px;}
  .nav-links{display:none;}
  section{padding:64px 6vw;}
  .about-grid,.theta-wrap,.alloc-grid,.sw-grid,.diag-grid{grid-template-columns:1fr;gap:40px;}
  .comp-grid{grid-template-columns:1fr 1fr;}
  .beliefs-grid{grid-template-columns:1fr;}
  .hero{padding:0 6vw 64px;}
  .hero-meta{flex-wrap:wrap;gap:22px;}
  .hero-dna{display:none;}
  .timeline{padding-left:90px;}
  .tl-year{left:-90px;width:72px;font-size:18px;}
  .belief-strip{padding:48px 6vw;}
  footer{flex-direction:column;gap:12px;text-align:center;}
  .arch-card-grid{grid-template-columns:1fr 1fr;}
}
</style>
</head>
<body>

<nav>
  <div class="nav-logo">Roche Diagnostics</div>
  <div class="nav-links">
    <a href="#about">About</a>
    <a href="#ethos">Ethos</a>
    <a href="#timeline">Timeline</a>
    <a href="#theta-map">Theta Map</a>
    <a href="#competitors">Rivals</a>
    <a href="#diagnostic">Diagnostic</a>
  </div>
</nav>

<!-- HERO -->
<section class="hero">
  <div class="hero-grid"></div>
  <div class="hero-orb1"></div>
  <div class="hero-orb2"></div>
  <div class="hero-dna">Râ‚“</div>
  <div class="hero-content">
    <div class="hero-label">Theta Framework Â· Strategic Case Study</div>
    <h1 class="hero-headline">The laboratory doesn't just<br>run the test. It decides<br><em>which therapy you receive.</em></h1>
    <p class="hero-sub">Roche Diagnostics sits at one of the rarest intersections in modern medicine â€” the place where a blood result doesn't just describe your condition, but selects your cure. No other diagnostics company on earth has built the pharmaceutical counterpart to make that loop real.</p>
    <div class="hero-meta">
      <div class="meta-item"><span class="meta-label">Diagnostics Founded</span><span class="meta-value">1898</span></div>
      <div class="meta-item"><span class="meta-label">Employees (Global)</span><span class="meta-value">~100,000</span></div>
      <div class="meta-item"><span class="meta-label">2025 Revenue</span><span class="meta-value">~14B CHF</span></div>
      <div class="meta-item"><span class="meta-label">Theta Archetype</span><span class="meta-value">Transitioning</span></div>
    </div>
  </div>
  <div class="scroll-cue">
    <div class="scroll-line"></div>
    <span class="scroll-text">Scroll</span>
  </div>
</section>

<!-- ABOUT -->
<section id="about" class="white">
  <div class="section-label">What Roche Diagnostics Actually Is</div>
  <h2 class="section-title">The world's largest <em>in vitro</em><br>diagnostics company â€” and<br>the one most likely to know<br>your diagnosis before you do.</h2>
  <div class="about-grid reveal">
    <div class="about-prose">
      <p>There is a phrase buried inside Roche Diagnostics' operating philosophy that most press releases skip over: "Doing now what patients need next." It sounds like a tagline. It is actually a timeline â€” a commitment that the lab results being processed in 2026 must anticipate clinical needs that won't be fully visible until 2030. In a business where the average diagnostic test takes a decade to develop, validate, and certify, this is not marketing language. It is the only logic that makes the investment rational.</p>
      <p>Roche Diagnostics doesn't run hospitals. It doesn't prescribe. What it does is far more structurally powerful: it provides the interpretive layer between a biological sample and a clinical decision. In immunoassays, oncology tissue diagnostics, molecular pathology, and now AI-driven digital pathology, Roche is the intelligence substrate of the modern lab. And since 1998, when Roche acquired Boehringer Mannheim to instantly become the global #1 in IVD, it has been using that substrate to gradually, methodically, and rather quietly build something no competitor can replicate: a closed loop between diagnosis and treatment.</p>
      <div class="dark-card">
        <div class="dark-card-label">The fact almost no one mentions</div>
        <p>Roche's parent company, F. Hoffmann-La Roche, was founded in 1896 by a 28-year-old entrepreneur named Fritz Hoffmann-La Roche who had no medical training. He was a textiles merchant's son who believed, against the scientific consensus of his era, that medicines could be manufactured at industrial scale and sold by brand name â€” not compounded one prescription at a time. He was right. The first product was a proprietary cough syrup. The company that grew from it now runs the most sophisticated companion diagnostic pipeline in the world, matching molecular cancer markers to targeted therapies with a precision that Fritz's contemporaries would have considered speculative fiction.</p>
      </div>
    </div>
    <div>
      <div class="stat-grid">
        <div class="stat-box">
          <div class="stat-num">#1</div>
          <div class="stat-desc">Global market position in in vitro diagnostics â€” held and extended continuously since the 1998 Boehringer Mannheim acquisition</div>
        </div>
        <div class="stat-box">
          <div class="stat-num">+25%</div>
          <div class="stat-desc">Growth in companion diagnostics in 2025 â€” the single fastest-growing category, powered by the pharma-diagnostics loop</div>
        </div>
        <div class="stat-box">
          <div class="stat-num">39</div>
          <div class="stat-desc">Tests on the cobasÂ® Mass Spec platform as of late 2025, including newly CE-marked antibiotic drug monitoring assays</div>
        </div>
        <div class="stat-box">
          <div class="stat-num">92.4%</div>
          <div class="stat-desc">KLAS performance score for navify Clinical Hub for Tumor Boards â€” vs. a category average of 80.3%</div>
        </div>
      </div>
    </div>
  </div>

  <div class="belief-strip reveal">
    <div class="belief-quote">"The goal is not to run more tests. The goal is to run the right test â€” and to have built the drug that the right test selects."</div>
    <div class="belief-attr">The "Diagnosing and Treating" philosophy â€” Roche Group's strategic axis</div>
  </div>
</section>

<!-- ETHOS / BELIEFS -->
<section id="ethos" class="warm">
  <div class="section-label">The Belief System</div>
  <h2 class="section-title">Six convictions that explain<br>why Roche builds things<br><em>the way it does.</em></h2>
  <div class="beliefs-grid reveal">
    <div class="belief-card">
      <div class="belief-num">01</div>
      <div class="belief-title">The Loop Is the Moat</div>
      <div class="belief-body">Most diagnostics companies sell tests. Roche sells certainty â€” and certainty is more valuable when the same organization that identified the mutation is also developing the drug that targets it. The companion diagnostic business isn't a product category at Roche. It's the proof that the loop is real: your test selects your therapy, and both were built in the same building.</div>
    </div>
    <div class="belief-card">
      <div class="belief-num">02</div>
      <div class="belief-title">Open Beats Proprietary â€” Eventually</div>
      <div class="belief-body">For a company whose core asset has always been proprietary instrumentation and reagent lock-in, the decision to launch an open digital ecosystem in navify represents a genuine philosophical shift. The navify Algorithm Suite invites third-party algorithms to compete on Roche's platform. The Digital Pathology Open Environment lets outside developers build on uPath. This is not generosity â€” it is the recognition that the value in a platform era is in the network, not the node.</div>
    </div>
    <div class="belief-card">
      <div class="belief-num">03</div>
      <div class="belief-title">A Sense of Purpose Cannot Be Ordered</div>
      <div class="belief-body">In 2002, Roche Diagnostics Germany launched "Meine Arbeitswelt" â€” "My Work World" â€” a culture transformation programme for 10,000 employees built on one uncomfortable admission: that enthusiasm cannot be commanded. The programme used anonymous digital feedback, cross-rank dialogue, and structured listening exercises. It predated every "employee engagement" methodology that consultants would later package and sell. The insight it generated â€” that transformation requires belonging before it produces behaviour change â€” still shapes how Roche approaches its digital transformation today.</div>
    </div>
    <div class="belief-card">
      <div class="belief-num">04</div>
      <div class="belief-title">The Lab Is a Living System, Not a Factory</div>
      <div class="belief-body">Roche's cobasÂ® ecosystem â€” its flagship integrated lab platform â€” isn't sold as a machine. It's sold as a workflow. The distinction matters: a machine processes samples; a workflow learns from them, connects them, and feeds the data upstream. The leap to navify Analytics and AI-driven pathology is the natural continuation of this logic â€” the lab as a continuous intelligence loop, not a batch-processing facility.</div>
    </div>
    <div class="belief-card">
      <div class="belief-num">05</div>
      <div class="belief-title">"In China, For China" Is Strategy, Not Compliance</div>
      <div class="belief-body">Roche's 3 billion yuan Suzhou expansion â€” announced in 2024, completing by 2028 â€” is not a response to regulatory pressure. It is the recognition that the Chinese market is creating its own biomarker science, its own clinical protocols, and its own diagnostic standards. The first domestically developed Roche product (Elecsys CA 242, for gastrointestinal cancers) launched in 2024. By 2030, over 400 localized products are planned. The shift from "product introducer" to "local innovation driver" is a different business model, not a different distribution route.</div>
    </div>
    <div class="belief-card">
      <div class="belief-num">06</div>
      <div class="belief-title">The Startup Relationship Starts Before the Acquisition</div>
      <div class="belief-body">Roche's open ecosystem is partly a startup engagement strategy. EarlySign, Binary Tech, TestCard â€” these are small companies whose products now live inside Roche's distribution network. The partnership starts before any acquisition discussion. By the time an M&A conversation becomes possible, the cultural bridge has already been built. Roche gets access to agile innovation; the startup gets global scale. And both parties arrive at any future integration having already survived a working relationship â€” which is more than most acquirers can say.</div>
    </div>
  </div>
</section>

<!-- TIMELINE -->
<section id="timeline" class="white">
  <div class="section-label">The Arc</div>
  <h2 class="section-title">From a cough syrup<br>and a bet on branding â€”<br>to <em>the world's diagnostic engine.</em></h2>
  <div class="timeline reveal">
    <div class="tl-spine"></div>

    <div class="tl-item">
      <div class="tl-year">1896</div>
      <div class="tl-dot filled"></div>
      <div class="tl-phase">Origin</div>
      <div class="tl-event">Fritz Hoffmann's Bet on Branded Medicine</div>
      <div class="tl-desc">F. Hoffmann-La Roche is founded in Basel by a 28-year-old with no medical training and one conviction: that medicines manufactured at industrial scale and sold under a brand name were more trustworthy than pharmacy-compounded preparations. The first product is Thiocol, a cough remedy. The company that grows from this idea will eventually run the world's most sophisticated cancer diagnostic pipeline.</div>
    </div>

    <div class="tl-item">
      <div class="tl-year">1964</div>
      <div class="tl-dot filled"></div>
      <div class="tl-phase">American Roots</div>
      <div class="tl-event">Bio-Dynamics Founded in Indianapolis</div>
      <div class="tl-desc">The US diagnostics story begins with Bio-Dynamics in Indianapolis â€” later acquired by Boehringer Mannheim Corporation in 1974. This lineage matters because it establishes a manufacturing and scientific heritage in the American Midwest that Roche Diagnostics still operates from today, as its largest single-country employer outside Germany.</div>
    </div>

    <div class="tl-item">
      <div class="tl-year">1998</div>
      <div class="tl-dot accent"></div>
      <div class="tl-phase">Inflection Point</div>
      <div class="tl-event">Boehringer Mannheim Acquired â€” the Instant Crown</div>
      <div class="tl-desc">Roche acquires Boehringer Mannheim for $11 billion â€” at the time, one of the largest deals in the diagnostics industry's history. Overnight, Roche becomes the world's #1 IVD company. The strategic insight behind the acquisition is deceptively simple: the best diagnostics business is one connected to the best pharmaceutical pipeline. What Roche now holds is the infrastructure to make that connection systemic.</div>
    </div>

    <div class="tl-item">
      <div class="tl-year">2002</div>
      <div class="tl-dot filled"></div>
      <div class="tl-phase">Cultural Inflection</div>
      <div class="tl-event">"Meine Arbeitswelt" â€” Before Employee Engagement Was a Discipline</div>
      <div class="tl-desc">Roche Diagnostics Germany launches a workforce culture programme using anonymous digital questionnaires and team feedback sessions for 10,000 employees. The premise â€” that purpose cannot be mandated â€” is radical for a manufacturing organisation in 2002. It predates every major employee engagement framework that management consultancies would later productize. The methodology still informs how Roche approaches technology adoption transformation today.</div>
    </div>

    <div class="tl-item">
      <div class="tl-year">2015â€“2023</div>
      <div class="tl-dot filled"></div>
      <div class="tl-phase">China Strategy</div>
      <div class="tl-event">Suzhou: Building the Local Science Base</div>
      <div class="tl-desc">Roche's Suzhou manufacturing and R&D presence grows through six successive expansions â€” reagents, instruments, PCR materials, tissue diagnosis, R&D centre, and new instrument plants. Each phase localises a different layer of the diagnostic process. The strategy is not vertical integration for efficiency; it is vertical localisation for irreversibility. By 2024, Roche produces its first entirely domestically developed Chinese product: Elecsys CA 242, a gastrointestinal cancer marker.</div>
    </div>

    <div class="tl-item">
      <div class="tl-year">2021â€“2024</div>
      <div class="tl-dot accent"></div>
      <div class="tl-phase">Digital Inflection</div>
      <div class="tl-event">navify Launches â€” the Open Ecosystem Bet</div>
      <div class="tl-desc">Roche launches navify as its digital diagnostic platform, initially for point-of-care operations and lab workflow. The navify Algorithm Suite â€” formally launched in early 2026 â€” extends this into an open marketplace for clinical algorithms, starting with oncology. EarlySign (colon cancer risk), Apollo Hospitals (74+ hospitals across India), and chest pain triage algorithms via Heidelberg follow. The KLAS scores arrive: 92.4% for Clinical Hub. 100% customer satisfaction across four product categories. The open ecosystem thesis begins to produce real-world validation.</div>
    </div>

    <div class="tl-item">
      <div class="tl-year">2024â€“2025</div>
      <div class="tl-dot filled"></div>
      <div class="tl-phase">Reckoning & Renewal</div>
      <div class="tl-event">China Decline, Quality Crisis, and the Legal Test</div>
      <div class="tl-desc">Three challenges arrive simultaneously. China revenues fall 28% in H1 2025 as government volume-based procurement cuts immunoassay prices by nearly 50%. A breast cancer test kit flaw potentially affects 300 Israeli patients â€” handled with transparency, but a reputational wound. And a lawsuit against Stanford and Foresight Diagnostics alleges misappropriation of Roche's liquid biopsy trade secrets. The company that emerges from 2025 is one that has been tested on quality, ethics, and IP â€” all at once.</div>
    </div>

    <div class="tl-item">
      <div class="tl-year">2026+</div>
      <div class="tl-dot"></div>
      <div class="tl-phase">Horizon</div>
      <div class="tl-event">SBX, Alzheimer's, and the Genome in Four Hours</div>
      <div class="tl-desc">Roche's SBX (sequencing-by-expansion) technology â€” launching in 2026 â€” decodes a full human genome in under four hours. This is not an incremental improvement on existing NGS platforms. It is a structural acceleration that collapses the time between genetic suspicion and therapeutic certainty. Combined with the p-Tau217 Alzheimer's blood assay (TIME's Best Inventions, 2024) and a growing CSF diagnostic pipeline, Roche is quietly preparing to do for neurology what it has already done for oncology.</div>
    </div>
  </div>
</section>

<!-- THETA MAP -->
<section id="theta-map" class="warm">
  <div class="section-label">Theta Innovation Map</div>
  <h2 class="section-title">Where each initiative sits â€”<br>and what the <em>portfolio geometry</em><br>reveals about the decade ahead.</h2>
  <div class="theta-wrap reveal">
    <div>
      <div class="zone-pill core">
        <div class="zone-pill-name">ðŸŸ© Core Zone</div>
        <div class="zone-pill-desc">cobas integrated platforms, immunoassay test menus, clinical chemistry, core lab automation, global service contracts. The 14B CHF engine that funds everything else.</div>
      </div>
      <div class="zone-pill edge">
        <div class="zone-pill-name">ðŸŸ¨ Edge Zone</div>
        <div class="zone-pill-desc">navify Algorithm Suite, Digital Pathology Open Environment, cobas Mass Spec, SBX sequencing. Architectural reconfiguration of how diagnostics reach clinicians.</div>
      </div>
      <div class="zone-pill beyond">
        <div class="zone-pill-name">ðŸŸ¥ Beyond Zone</div>
        <div class="zone-pill-desc">"Diagnosing and Treating" as a clinical standard, Alzheimer's diagnostic-therapeutic pathway, AI-native biomarker discovery. The terrain that requires a pharmaceutical partner to enter.</div>
      </div>
      <div class="reading-box">
        <div class="reading-box-label">Reading This Map</div>
        <p>The most structurally important feature of Roche's innovation map is not any single initiative â€” it is the diagonal trajectory. Each major bet moves right and up simultaneously: broader market reach and higher technological change. The SBX platform and navify both follow this pattern. The Alzheimer's programme, uniquely, can only be funded because Roche Pharma is building the drug that the diagnostic will select. That co-dependency is both the deepest moat and the deepest risk in the portfolio.</p>
      </div>
    </div>
    <div class="chart-h">
      <canvas id="scatterChart"></canvas>
    </div>
  </div>
</section>

<!-- ALLOCATION -->
<section class="white">
  <div class="section-label">Portfolio Allocation</div>
  <h2 class="section-title">The weight behind<br><em>the transition</em> â€” and where<br>it diverges from the benchmark.</h2>
  <div class="alloc-grid reveal">
    <div class="donut-wrap">
      <canvas id="donutChart" style="max-width:270px;max-height:270px;"></canvas>
      <div class="donut-center">
        <span class="donut-center-lbl">Zones Active</span>
        <span class="donut-center-val">3</span>
      </div>
    </div>
    <div class="alloc-bars">
      <div>
        <div class="bar-header">
          <span class="bar-name" style="color:var(--core-green)">Core Zone</span>
          <span class="bar-pcts">~75% actual Â· 70% benchmark</span>
        </div>
        <div class="bar-track">
          <div class="bar-fill" style="width:75%;background:var(--core-green);"></div>
          <div class="bar-bm" style="left:70%;"></div>
        </div>
        <div class="bar-comment">Slightly overweight â€” a function of the immunoassay installed base and the sheer breadth of the test menu. Core is healthy but under China pricing pressure. The risk is not starvation of the future; it is distraction from it when quarterly numbers soften.</div>
      </div>
      <div>
        <div class="bar-header">
          <span class="bar-name" style="color:var(--edge-amber)">Edge Zone</span>
          <span class="bar-pcts">~16% actual Â· 20% benchmark</span>
        </div>
        <div class="bar-track">
          <div class="bar-fill" style="width:16%;background:var(--edge-amber);"></div>
          <div class="bar-bm" style="left:20%;"></div>
        </div>
        <div class="bar-comment">Below benchmark but gaining momentum. navify's 90%+ KLAS scores and the Apollo Hospitals partnership (74+ hospitals, January 2026) signal the platform is crossing from early adopter to early majority. The gap to 20% represents real investment headroom â€” and real urgency.</div>
      </div>
      <div>
        <div class="bar-header">
          <span class="bar-name" style="color:var(--beyond-crimson)">Beyond Zone</span>
          <span class="bar-pcts">~7% actual Â· 10% benchmark</span>
        </div>
        <div class="bar-track">
          <div class="bar-fill" style="width:7%;background:var(--beyond-crimson);"></div>
          <div class="bar-bm" style="left:10%;"></div>
        </div>
        <div class="bar-comment">Below benchmark but uniquely concentrated. Roche's Beyond bets are not speculative â€” they are the pharma-diagnostics loop made real. The Alzheimer's programme alone represents a clinical category that does not yet have a treatment standard. Roche is building the test and the drug simultaneously. That is not a 10% bet. It is a decadal wager.</div>
      </div>
    </div>
  </div>

  <div style="margin-top:64px;" class="reveal">
    <div class="chart-label">Roche Diagnostics Revenue â€” CHF Billions (Fiscal Year)</div>
    <div class="rev-wrap">
      <canvas id="revenueChart"></canvas>
    </div>
  </div>
</section>

<!-- STRATEGIC ARCHITECTURE -->
<section class="warm">
  <div class="section-label">The Strategic Architecture</div>
  <h2 class="section-title">Three bets Roche is making<br>that its competitors <em>cannot</em><br>simply replicate by spending.</h2>
  <div class="arch-card-grid reveal">
    <div class="arch-card">
      <div class="arch-card-yr">Loop</div>
      <div class="arch-card-name">The Pharma-Diagnostics Closed Circuit</div>
      <div class="arch-card-desc">Roche builds the cancer test and the cancer drug. When the VENTANA HER2 assay identifies a patient's tumour type, it is selecting for a Roche therapy. This is not co-marketing â€” it is co-development. Companion diagnostics grew 25% in 2025 while the market contracted. The loop is real, and no competitor without a pharmaceutical division can enter it.</div>
      <span class="arch-card-status live">Active Â· Growing</span>
    </div>
    <div class="arch-card">
      <div class="arch-card-yr">Open</div>
      <div class="arch-card-name">navify: The Algorithm Marketplace No One Saw Coming</div>
      <div class="arch-card-desc">Roche spent a century building proprietary reagent lock-in. navify inverts this: third-party algorithms from EarlySign, Binary Tech, TestCard, and others now live inside the Roche platform. The strategic logic is ecosystem density â€” more algorithms make the platform more valuable than any single Roche product could. The Apollo Hospitals partnership is the first large-scale test of whether this density can scale across a tier-1 healthcare network in a middle-income market.</div>
      <span class="arch-card-status growing">Scaling</span>
    </div>
    <div class="arch-card">
      <div class="arch-card-yr">Local</div>
      <div class="arch-card-name">Suzhou: Innovation at the Price Point China Requires</div>
      <div class="arch-card-desc">The 3 billion yuan Suzhou expansion is not a manufacturing efficiency play. It is a product relevance play. By developing assays for gastrointestinal cancers and other disease profiles more prevalent in East Asia, Roche is not adapting its global catalogue for China â€” it is building a China catalogue that will expand globally. The 400 localized products planned by 2030 represent a second product engine, not a regional supplement.</div>
      <span class="arch-card-status challenge">Under Pressure Â· Investing Through It</span>
    </div>
    <div class="arch-card">
      <div class="arch-card-yr">Speed</div>
      <div class="arch-card-name">SBX: A Genome in Under Four Hours</div>
      <div class="arch-card-desc">Sequencing-by-expansion (SBX) is a proprietary reading method that does not require the optical systems that make current NGS platforms bulky and slow. The result: a full human genome in under four hours, with accuracy and cost profiles that could push genomic sequencing from specialist oncology centres into routine diagnostic labs. Launching in 2026, SBX is Roche's most technically disruptive bet since the PCR licensing era of the 1990s.</div>
      <span class="arch-card-status growing">Launching 2026</span>
    </div>
    <div class="arch-card">
      <div class="arch-card-yr">Mind</div>
      <div class="arch-card-name">Alzheimer's: The Diagnostic Before the Disease Speaks</div>
      <div class="arch-card-desc">The p-Tau217 blood assay named in TIME's Best Inventions of 2024 is not a diagnostic for Alzheimer's disease as it presents clinically. It is a diagnostic for Alzheimer's pathology years before symptoms appear. Combined with Roche Pharma's neurological pipeline, this creates the same closed loop that VENTANA created for oncology â€” but in a disease category where no treatment standard yet exists. Roche is not detecting Alzheimer's. It is building the market that treatment will enter.</div>
      <span class="arch-card-status growing">Frontier Â· TIME Best Inventions 2024</span>
    </div>
    <div class="arch-card">
      <div class="arch-card-yr">Mass</div>
      <div class="arch-card-name">cobas Mass Spec: The Gold Standard, Automated</div>
      <div class="arch-card-desc">Mass spectrometry has been the reference standard in analytical chemistry for decades â€” precise, sensitive, and until recently, too complex and labour-intensive for routine diagnostic labs. cobas Mass Spec automates the full workflow, brings 39-test menus including antibiotic drug monitoring (CE Mark, late 2025), and won Best New Clinical Diagnostics Instrumentation of 2024. This is architectural innovation in the Theta sense: same clinical principle, radically different delivery model.</div>
      <span class="arch-card-status live">CE Marked Â· Expanding</span>
    </div>
  </div>
</section>

<!-- COMPETITORS -->
<section id="competitors" class="white">
  <div class="section-label">Competitive Landscape</div>
  <h2 class="section-title">The four rivals Roche must<br><em>outinnovate, outlocalise,</em><br>and occasionally out-wait.</h2>
  <div class="comp-grid reveal">
    <div class="comp-card featured">
      <div class="comp-name">Roche</div>
      <div class="comp-tag">IVD global leader Â· Pharma loop</div>
      <div class="comp-zones">
        <div class="comp-zone-row"><div class="zdot core"></div><span>Dominant â€” broadest test menu globally</span></div>
        <div class="comp-zone-row"><div class="zdot edge"></div><span>Leading â€” navify, SBX, Mass Spec</span></div>
        <div class="comp-zone-row"><div class="zdot beyond"></div><span>Unique â€” pharma loop; Alzheimer's</span></div>
      </div>
      <span class="verdict-chip leader">Transitioning</span>
    </div>
    <div class="comp-card">
      <div class="comp-name">Abbott</div>
      <div class="comp-tag">POC powerhouse Â· Cancer pivot</div>
      <div class="comp-zones">
        <div class="comp-zone-row"><div class="zdot core"></div><span>Dominant in POC (i-STAT, BinaxNOW)</span></div>
        <div class="comp-zone-row"><div class="zdot edge"></div><span>Transformative â€” Exact Sciences acquisition</span></div>
        <div class="comp-zone-row"><div class="zdot beyond"></div><span>Emerging â€” Cologuard, Oncotype DX</span></div>
      </div>
      <span class="verdict-chip challenger">High-Stakes Pivot</span>
    </div>
    <div class="comp-card">
      <div class="comp-name">Danaher</div>
      <div class="comp-tag">Operational excellence Â· Diverse portfolio</div>
      <div class="comp-zones">
        <div class="comp-zone-row"><div class="zdot core"></div><span>Best-in-class â€” Beckman, Cepheid, Leica</span></div>
        <div class="comp-zone-row"><div class="zdot edge"></div><span>Portfolio-spread â€” GeneXpert strength</span></div>
        <div class="comp-zone-row"><div class="zdot beyond"></div><span>Limited â€” operational over visionary</span></div>
      </div>
      <span class="verdict-chip leader">Execution Winner</span>
    </div>
    <div class="comp-card">
      <div class="comp-name">Siemens Healthineers</div>
      <div class="comp-tag">Imaging-first Â· Diagnostics secondary</div>
      <div class="comp-zones">
        <div class="comp-zone-row"><div class="zdot core"></div><span>Strong â€” Atellica, lab automation</span></div>
        <div class="comp-zone-row"><div class="zdot edge"></div><span>Imaging-led â€” syngo, Varian synergy</span></div>
        <div class="comp-zone-row"><div class="zdot beyond"></div><span>Thin â€” IVD is the "weakest piece"</span></div>
      </div>
      <span class="verdict-chip laggard">Imaging Giant, IVD Follower</span>
    </div>
    <div class="comp-card">
      <div class="comp-name">Mindray / Seegene</div>
      <div class="comp-tag">Emerging challengers Â· Price aggression</div>
      <div class="comp-zones">
        <div class="comp-zone-row"><div class="zdot core"></div><span>Cost-competitive in core markets</span></div>
        <div class="comp-zone-row"><div class="zdot edge"></div><span>Growing â€” emerging market digital ambition</span></div>
        <div class="comp-zone-row"><div class="zdot beyond"></div><span>Early â€” building innovation infrastructure</span></div>
      </div>
      <span class="verdict-chip challenger">Price Disruptors</span>
    </div>
  </div>
  <div class="radar-wrap reveal">
    <canvas id="radarChart"></canvas>
  </div>
</section>

<!-- S&W -->
<section class="warm">
  <div class="section-label">Strategic Assessment</div>
  <h2 class="section-title">The genuine strengths,<br>and the <em>honest tensions</em><br>the strategy must carry.</h2>
  <div class="sw-grid reveal">
    <div class="sw-panel str">
      <div class="sw-title">What Is Real</div>
      <div class="sw-item">
        <div class="sw-marker">S</div>
        <div>
          <div class="sw-lead">The pharma loop is not a strategy. It is a structural advantage.</div>
          <div class="sw-body">No IVD competitor without a pharmaceutical division can replicate the companion diagnostic flywheel. When a VENTANA test selects a patient for a Roche oncology drug, the economics of both businesses improve simultaneously. This co-development architecture is decades old and gets harder to dislodge the more companion diagnostic approvals accumulate â€” there are now hundreds.</div>
        </div>
      </div>
      <div class="sw-item">
        <div class="sw-marker">S</div>
        <div>
          <div class="sw-lead">navify's KLAS scores are not launch optimism â€” they are validation.</div>
          <div class="sw-body">KLAS research is independent, provider-led, and notoriously hard to game. Scores above 90% across four navify product categories, with 100% customer satisfaction ratings and 86% of Clinical Hub customers reporting tangible outcomes within six months, represent real-world proof of concept â€” not product announcements. The Ellis Fischel and San Raffaele case studies provide the quantitative spine: 40â€“68% efficiency improvements on measurable clinical workflows.</div>
        </div>
      </div>
      <div class="sw-item">
        <div class="sw-marker">S</div>
        <div>
          <div class="sw-lead">The open ecosystem inverts decades of reagent lock-in â€” deliberately.</div>
          <div class="sw-body">Roche built a multi-billion business on selling cobas instruments that only ran Roche reagents. The decision to open navify to third-party algorithms is strategically costly in the short term and strategically necessary in the long term. Platform value compounds through network density. Roche has chosen ecosystem leadership over product control â€” a bet that is structurally correct and culturally difficult for a hardware-first organisation to execute.</div>
        </div>
      </div>
      <div class="sw-item">
        <div class="sw-marker">S</div>
        <div>
          <div class="sw-lead">The Alzheimer's diagnostic is building the market, not entering it.</div>
          <div class="sw-body">p-Tau217 detects Alzheimer's pathology before symptoms. There is currently no approved treatment standard for this stage. Roche Pharma is in the neurological pipeline. The combination means Roche Diagnostics is not competing in an existing Alzheimer's testing market â€” it is creating the clinical standard that the market will eventually require. This is the most asymmetric bet in the portfolio.</div>
        </div>
      </div>
      <div class="sw-item">
        <div class="sw-marker">S</div>
        <div>
          <div class="sw-lead">Suzhou is building a second product engine, not a regional depot.</div>
          <div class="sw-body">The 400 localized products planned for China and Asia-Pacific by 2030 are not adaptations of Western assays â€” they include disease markers specific to East Asian epidemiology. When these products mature, they will enter global portfolios as genuine innovations from the Chinese R&D base, not compliance gestures. The CA 242 gastrointestinal cancer assay is the prototype.</div>
        </div>
      </div>
    </div>
    <div class="sw-panel wk">
      <div class="sw-title">What Is Hard</div>
      <div class="sw-item">
        <div class="sw-marker">W</div>
        <div>
          <div class="sw-lead">China's 28% revenue decline is structural, not cyclical.</div>
          <div class="sw-body">Volume-based procurement in China cut immunoassay prices by nearly 50%. This is not a downturn that recovers when sentiment improves â€” it is a policy architecture that permanently reprices Roche's highest-volume test categories in the world's fastest-growing healthcare market. The Suzhou localization strategy is the correct counter-move, but it takes until 2028 to complete, and the revenue gap is live now.</div>
        </div>
      </div>
      <div class="sw-item">
        <div class="sw-marker">W</div>
        <div>
          <div class="sw-lead">The cancer test kit quality failure is a permanent reminder of what scale demands.</div>
          <div class="sw-body">The 2025 breast cancer test kit flaw â€” a staining intensity defect that potentially affected 300 Israeli patients and may have led to incorrect hormonal therapy decisions â€” was handled transparently: halt, destroy stock, notify labs. But transparency after the fact does not erase the question of what allowed a quality issue to reach clinical use at this scale. For a company whose entire value proposition rests on diagnostic accuracy, a quality failure is an existential credibility event.</div>
        </div>
      </div>
      <div class="sw-item">
        <div class="sw-marker">W</div>
        <div>
          <div class="sw-lead">The hardware-to-software transition creates a cultural gap that no org chart resolves.</div>
          <div class="sw-body">cobas instrument engineers think in hardware cycles â€” multi-year, deterministic, linear. navify product teams think in software sprints â€” iterative, probabilistic, continuous. These are not just different working styles; they are different epistemologies about what a "good product" means. Roche's "Meine Arbeitswelt" precedent shows it has understood culture-led transformation before. Whether that institutional memory translates to the digital transition is unproven.</div>
        </div>
      </div>
      <div class="sw-item">
        <div class="sw-marker">W</div>
        <div>
          <div class="sw-lead">Point-of-care is a structural weakness in an era of decentralized testing.</div>
          <div class="sw-body">Near-patient care revenue fell 4% in 2025, with Liat System PCR diagnostics down 5% and blood glucose monitors down 2%. Abbott's i-STAT and Alinity series dominate decentralized testing with a portfolio depth Roche cannot match. As healthcare systems push diagnostics closer to the patient â€” in pharmacies, homes, and primary care â€” Roche's core competency in centralized lab instrumentation becomes a geographic liability.</div>
        </div>
      </div>
      <div class="sw-item">
        <div class="sw-marker">W</div>
        <div>
          <div class="sw-lead">The Stanford lawsuit reveals what the open ecosystem cannot protect.</div>
          <div class="sw-body">Roche's lawsuit alleging that Stanford professors used access to its CAPP-Seq liquid biopsy technology to develop a competing platform (PhasED-Seq) through Foresight Diagnostics is a direct consequence of the collaboration model. Open ecosystems create access, and access creates exposure. The more Roche opens its platforms to research partners, startups, and academic centres, the more complex its IP boundary management must become. The case is unresolved. The tension it names is permanent.</div>
        </div>
      </div>
    </div>
  </div>
</section>

<!-- DIAGNOSTIC -->
<section id="diagnostic" class="ink">
  <div class="section-label">Theta Diagnostic</div>
  <h2 class="section-title">The portrait that emerges<br>when you read all three zones<br><em>together, not in sequence.</em></h2>
  <div class="diag-grid reveal">
    <div>
      <div class="diag-block">
        <div class="diag-block-title">Portfolio Archetype</div>
        <div class="arch-row">
          <span class="arch-box ok">Core âœ“</span>
          <span class="arch-box mid">Edge â–³</span>
          <span class="arch-box ok">Beyond âœ“</span>
        </div>
        <p class="diag-prose" style="margin-top:12px;">Three zones active, but not in proportion. The Core is healthy but under pricing pressure in its most exposed geography. The Edge is producing real results but not yet at the allocation level the transition requires. The Beyond is concentrated rather than broad â€” two or three long-horizon bets rather than a speculative portfolio. The archetype is Transitioning: deliberate movement in the right direction, with the Core still carrying more than its intended share of the strategic weight.</p>
      </div>

      <div class="diag-block">
        <div class="diag-block-title">Cultural & Leadership Reading</div>
        <p class="diag-prose">The most revealing data point in Roche's leadership culture is the question Moritz Hartmann asked publicly at HIMSS24: do organisations need to "take employees along" during automation transformation? A leader who asks this question in a public forum is not looking for an answer â€” they already know the answer is yes. They are signalling to the organisation that this is a leadership value, not a programme. The "Meine Arbeitswelt" precedent from 2002 suggests this instinct has institutional roots. The question is whether a legacy hardware organisation of 100,000 people can operationalise that instinct at the speed the software transition demands.</p>
      </div>

      <div class="diag-block">
        <div class="diag-block-title">The Startup Bridge</div>
        <p class="diag-prose">Roche's approach to startups â€” early partnerships before any acquisition conversation â€” is a cultural bridge strategy that most acquirers discover only after the first failed integration. EarlySign, Binary Tech, and TestCard are not vendors. They are early relationship investments. The navify marketplace gives them distribution in exchange for validation of Roche's platform thesis. By the time an M&A process becomes relevant, both parties have already survived the hardest part of integration: working together under real clinical and commercial pressure.</p>
      </div>
    </div>

    <div>
      <div class="diag-block">
        <div class="diag-block-title">Zone Allocation vs. Benchmark</div>
        <div style="margin-top:14px;">
          <div class="ibr">
            <span class="ibr-label">Core</span>
            <div class="ibr-track">
              <div class="ibr-fill" style="width:75%;background:var(--core-green);"></div>
              <div class="ibr-bm" style="left:70%;"></div>
            </div>
            <span class="ibr-pct">75%</span>
          </div>
          <div class="ibr">
            <span class="ibr-label">Edge</span>
            <div class="ibr-track">
              <div class="ibr-fill" style="width:16%;background:var(--edge-amber);"></div>
              <div class="ibr-bm" style="left:20%;"></div>
            </div>
            <span class="ibr-pct">16%</span>
          </div>
          <div class="ibr">
            <span class="ibr-label">Beyond</span>
            <div class="ibr-track">
              <div class="ibr-fill" style="width:7%;background:var(--beyond-crimson);"></div>
              <div class="ibr-bm" style="left:10%;"></div>
            </div>
            <span class="ibr-pct">7%</span>
          </div>
          <p style="font-size:10px;color:rgba(255,255,255,0.18);margin-top:8px;">Vertical markers indicate Theta benchmark targets (70 / 20 / 10)</p>
        </div>
      </div>

      <div class="diag-block">
        <div class="diag-block-title">The Relativity Assessment</div>
        <p class="diag-prose">What Roche's open ecosystem strategy represents to a hardware company in 2026 is roughly what Siemens' open-sourcing of the dynamo principle represented in 1867: a bet that the value of accelerating the broader market exceeds the value of controlling it. Roche is not the most agile company in IVD â€” Danaher's operational system is superior. It is not the most aggressive in POC â€” Abbott has built that position over decades. What Roche has that no competitor can buy is the closed loop: the test, the drug, the data, and now the platform. That loop, if the transition holds, is the most defensible position in modern diagnostics.</p>
      </div>

      <div class="diag-block">
        <div class="diag-block-title">Critical Tension</div>
        <div class="tension-box">
          <div class="tension-label">The Platform Transition Needs the Core to Stay Healthy While It Happens</div>
          <div class="tension-text">navify's commercial momentum is real. The Apollo partnership is real. The SBX launch is real. But all of it is funded by cobas reagent revenue â€” the very revenue that China's volume-based procurement is systematically compressing. Roche must simultaneously defend its Core margins in a hostile pricing environment and accelerate Edge investment at a rate that outpaces competitors before they replicate the open ecosystem model. These two imperatives are not in conflict in principle. In practice, they compete for the same leadership attention, capital allocation decisions, and sales force incentives. The next two years will reveal whether the organisation can hold both tensions without resolving them prematurely in favour of the one that is easier to measure.</div>
        </div>
      </div>

      <div class="verdict-final">
        <div class="verdict-type">Transitioning â€” With a Unique Moat</div>
        <div class="verdict-symbols">âœ“ â–³ âœ“</div>
        <div class="verdict-explain">Roche Diagnostics is a Core-dominant company in active, deliberate transition toward Edge leadership â€” with a Beyond position that no competitor can enter without a pharmaceutical partner. The Core is healthy but pressured. The Edge is producing validated results but underfunded relative to the benchmark. The Beyond is concentrated, not broad â€” two or three bets of exceptional quality rather than a speculative portfolio. The Theta score is not a limitation. It is an accurate portrait of a 128-year-old hardware giant doing something genuinely difficult: opening itself up while defending what made it indispensable, and building the future market for diseases that do not yet have a treatment standard.</div>
      </div>
    </div>
  </div>
</section>

<footer>
  <div class="footer-l"><strong>Theta Framework</strong> Â· Roche Diagnostics Case Study Â· 2026</div>
  <div class="footer-r">Strategic Case Study</div>
</footer>

<script>
// Scroll reveal
const observer = new IntersectionObserver(entries => {
  entries.forEach(e => { if(e.isIntersecting) e.target.classList.add('visible'); });
}, { threshold: 0.05 });
document.querySelectorAll('.reveal').forEach(el => observer.observe(el));

const tt = {
  backgroundColor:'rgba(8,15,28,0.93)',
  titleColor:'#fff',
  bodyColor:'rgba(255,255,255,0.6)',
  titleFont:{family:'Outfit',size:12},
  bodyFont:{family:'Outfit',size:11},
  padding:10,cornerRadius:2,borderWidth:1,
  borderColor:'rgba(0,102,204,0.2)'
};

// Point label plugin
const pointLabelPlugin = {
  id:'pointLabels',
  afterDatasetsDraw(chart){
    const ctx = chart.ctx;
    chart.data.datasets.forEach((ds,i) => {
      chart.getDatasetMeta(i).data.forEach((point,j) => {
        const d = ds.data[j];
        if(d.label){
          ctx.save();
          ctx.fillStyle = ds.borderColor;
          ctx.font = '500 11px Outfit';
          ctx.textAlign = 'left';
          ctx.fillText(d.label, point.x + 11, point.y + 4);
          ctx.restore();
        }
      });
    });
  }
};

// Scatter chart
new Chart(document.getElementById('scatterChart').getContext('2d'), {
  type:'scatter',
  plugins:[pointLabelPlugin],
  data:{
    datasets:[
      {
        label:'Core Zone',
        data:[
          {x:10,y:12,label:'cobas Integration'},
          {x:22,y:16,label:'Immunoassay Menu'},
          {x:28,y:18,label:'Test Menu Expansion'},
          {x:16,y:10,label:'Core Lab Automation'},
        ],
        backgroundColor:'rgba(26,107,74,0.8)',borderColor:'#1A6B4A',pointRadius:8
      },
      {
        label:'Edge Zone',
        data:[
          {x:52,y:58,label:'navify Algorithm Suite'},
          {x:56,y:64,label:'Digital Pathology Open Env.'},
          {x:48,y:52,label:'cobas Mass Spec'},
          {x:62,y:72,label:'SBX Sequencing'},
        ],
        backgroundColor:'rgba(176,123,26,0.8)',borderColor:'#B07B1A',pointRadius:8
      },
      {
        label:'Beyond Zone',
        data:[
          {x:80,y:84,label:'Diag + Therapy Loop'},
          {x:86,y:92,label:"Alzheimer's (p-Tau217)"},
          {x:76,y:80,label:'AI Biomarker Discovery'},
        ],
        backgroundColor:'rgba(122,26,46,0.8)',borderColor:'#7A1A2E',pointRadius:8
      }
    ]
  },
  options:{
    responsive:true,maintainAspectRatio:false,
    plugins:{
      legend:{position:'bottom',labels:{font:{family:'Outfit',size:11},color:'#46555A',boxWidth:10,padding:18}},
      tooltip:{...tt,callbacks:{label:c=>c.raw.label||''}}
    },
    scales:{
      x:{min:0,max:108,
        title:{display:true,text:'Market Reach  â†’  Existing Â· New Â· Emerging Â· Speculative',font:{family:'Outfit',size:11},color:'#8A9099'},
        ticks:{display:false},grid:{color:'rgba(0,102,204,0.05)'},border:{display:false}},
      y:{min:0,max:108,
        title:{display:true,text:'Technology Change  â†’  Incremental Â· Moderate Â· High Â· Radical',font:{family:'Outfit',size:11},color:'#8A9099'},
        ticks:{display:false},grid:{color:'rgba(0,102,204,0.05)'},border:{display:false}}
    }
  }
});

// Donut
new Chart(document.getElementById('donutChart').getContext('2d'), {
  type:'doughnut',
  data:{
    labels:['Core Zone','Edge Zone','Beyond Zone'],
    datasets:[{data:[75,16,7],backgroundColor:['rgba(26,107,74,0.82)','rgba(176,123,26,0.82)','rgba(122,26,46,0.82)'],borderWidth:0,hoverOffset:6}]
  },
  options:{
    responsive:true,maintainAspectRatio:true,cutout:'68%',
    plugins:{
      legend:{position:'bottom',labels:{font:{family:'Outfit',size:11},color:'#46555A',boxWidth:10,padding:14}},
      tooltip:{...tt,callbacks:{label:c=>`${c.label}: ${c.raw}%`}}
    }
  }
});

// Revenue chart
new Chart(document.getElementById('revenueChart').getContext('2d'), {
  type:'bar',
  data:{
    labels:['FY2019','FY2020','FY2021','FY2022','FY2023','FY2024','FY2025'],
    datasets:[{
      label:'Revenue (CHF B)',
      data:[12.2,13.0,17.5,14.45,14.32,14.07,14.0],
      backgroundColor:['rgba(0,102,204,0.32)','rgba(0,102,204,0.36)','rgba(0,102,204,0.78)','rgba(0,102,204,0.42)','rgba(0,102,204,0.38)','rgba(0,102,204,0.36)','rgba(0,102,204,0.34)'],
      borderColor:'rgba(0,102,204,0.7)',borderWidth:1,borderRadius:2,hoverBackgroundColor:'rgba(0,170,255,0.5)'
    }]
  },
  options:{
    responsive:true,maintainAspectRatio:false,
    plugins:{
      legend:{display:false},
      tooltip:{...tt,callbacks:{label:c=>`CHF ${c.raw}B`}}
    },
    scales:{
      x:{grid:{display:false},ticks:{font:{family:'Outfit',size:11},color:'#8A9099'},border:{display:false}},
      y:{min:8,max:20,grid:{color:'rgba(0,102,204,0.06)'},ticks:{font:{family:'Outfit',size:10},color:'#8A9099',callback:v=>'CHF '+v+'B',maxTicksLimit:7},border:{display:false}}
    }
  }
});

// Radar
new Chart(document.getElementById('radarChart').getContext('2d'), {
  type:'radar',
  data:{
    labels:['Oncology Depth','Digital Ecosystem','Pharma Synergy','POC Strength','Operational Excellence','AI Readiness'],
    datasets:[
      {label:'Roche',data:[93,78,99,42,72,76],borderColor:'#0066CC',backgroundColor:'rgba(0,102,204,0.08)',borderWidth:2.5,pointBackgroundColor:'#0066CC',pointRadius:4},
      {label:'Abbott',data:[74,62,22,95,78,68],borderColor:'#B07B1A',backgroundColor:'rgba(176,123,26,0.05)',borderWidth:2,pointBackgroundColor:'#B07B1A',pointRadius:4},
      {label:'Danaher',data:[78,58,18,72,94,70],borderColor:'#1A6B4A',backgroundColor:'rgba(26,107,74,0.05)',borderWidth:2,pointBackgroundColor:'#1A6B4A',pointRadius:4},
      {label:'Siemens Healthineers',data:[68,60,28,55,76,74],borderColor:'#7A1A2E',backgroundColor:'rgba(122,26,46,0.04)',borderWidth:2,pointBackgroundColor:'#7A1A2E',pointRadius:4}
    ]
  },
  options:{
    responsive:true,maintainAspectRatio:true,
    plugins:{
      legend:{position:'bottom',labels:{font:{family:'Outfit',size:11},color:'#46555A',boxWidth:10,padding:14}},
      tooltip:tt
    },
    scales:{
      r:{min:0,max:100,
        ticks:{display:false},
        grid:{color:'rgba(0,0,0,0.07)'},
        angleLines:{color:'rgba(0,0,0,0.07)'},
        pointLabels:{font:{family:'Outfit',size:11},color:'#46555A'}
      }
    }
  }
});
</script>
</body>
</html>
